The Food and Drug Administration Office of Women's Health: Impact of Science on Regulatory Policy: An Update

The U.S. Food and Drug Administration Office of Women's Health (FDA OWH) has supported women's health research for ∼20 years, funding more than 300 studies on women's health issues, including research on diseases/conditions that disproportionately affect women in addition to the evaluation of sex differences in the performance of and response to medical products. These important women's health issues are studied from a regulatory perspective, with a focus on improving and optimizing medical product development and the evaluation of product safety and efficacy in women. These findings have influenced industry direction, labeling, product discontinuation, safety notices, and clinical practice. In addition, OWH-funded research has addressed gaps in the knowledge about diseases and medical conditions that impact women across the life span such as cardiovascular disease, pregnancy, menopause, osteoporosis, and the safe use of numerous medical products.

• Publication year

  2016

• Venue

  Journal of Women's Health

• Publication date

  2016-03-01

• Fields of study

  Medicine, Political Science

• Identifiers
  DOI 10.1089/jwh.2015.5671PMID 26871618PMCID 4790210
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of iron oxide nanoparticles on biological responses and MR imaging properties in human mammary healthy and breast cancer epithelial cells.

  2016cited by this paper
• Immunological characterization of the gluten fractions and their hydrolysates from wheat, rye and barley.

  2015cited by this paper
• Demographics of Clinical Trials Participants in Pivotal Clinical Trials for New Molecular Entity Drugs and Biologics Approved by FDA From 2010 to 2012

  2015influential reference
• Age and sex differences in kidney microRNA expression during the life span of F344 rats

  2015cited by this paper
• Comprehensive T wave Morphology Assessment in a Randomized Clinical Study of Dofetilide, Quinidine, Ranolazine, and Verapamil

  2015cited by this paper
• Investigation of potential mechanisms of sex differences in quinidine-induced torsade de pointes risk.

  2015cited by this paper
• Cardiac Resynchronization Therapy in Women Versus Men: Observational Comparative Effectiveness Study From the National Cardiovascular Data Registry

  2015cited by this paper
• The Effects of Processing on Gluten from Wheat, Rye, and Barley, and its Detection in Foods

  2015cited by this paper
• A rat RNA-Seq transcriptomic BodyMap across 11 organs and 4 developmental stages

  2014cited by this paper
• Physiologically Based Pharmacokinetic Modeling: From Regulatory Science to Regulatory Policy

  2014cited by this paper
• Transplacental Transfer of Hepatitis B Neutralizing Antibody during Pregnancy in an Animal Model: Implications for Newborn and Maternal Health

  2014cited by this paper
• Differentiating Drug‐Induced Multichannel Block on the Electrocardiogram: Randomized Study of Dofetilide, Quinidine, Ranolazine, and Verapamil

  2014cited by this paper
• Women's health, pregnancy, and the U.S. Food and Drug Administration.

  2014cited by this paper
• Metzincins and related genes in experimental renal ageing: towards a unifying fibrosis classifier across species.

  2014cited by this paper
• Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patient-level data.

  2014cited by this paper
• Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19.

  2014cited by this paper
• Clinical development success rates for investigational drugs

  2014cited by this paper
• Leaning toward a better understanding of CRT in women.

  2014cited by this paper
• Improving the Assessment of Heart Toxicity for All New Drugs Through Translational Regulatory Science

  2014cited by this paper
• Performance of a Redesigned HIV Selectest Enzyme-Linked Immunosorbent Assay Optimized To Minimize Vaccine-Induced Seropositivity in HIV Vaccine Trial Participants

  2014cited by this paper
• Sex-specific mortality risk by QRS morphology and duration in patients receiving CRT: results from the NCDR.

  2014cited by this paper
• Sex differences in kidney gene expression during the life cycle of F344 rats

  2013cited by this paper
• Participation of Women and Sex Analyses in Late-Phase Clinical Trials of New Molecular Entity Drugs and Biologics Approved by the FDA in 2007–2009

  2013cited by this paper
• Left bundle branch block predicts better survival in women than men receiving cardiac resynchronization therapy: long-term follow-up of ∼ 145,000 patients.

  2013cited by this paper
• Life Cycle Analysis of Kidney Gene Expression in Male F344 Rats

  2013cited by this paper
• Beyond mammography: new frontiers in breast cancer screening.

  2013cited by this paper
• Evaluation of Digested Wheat Gluten as a Proposed Reference Material for ELISA Analysis

  2013cited by this paper
• Trastuzumab Alters the Expression of Genes Essential for Cardiac Function and Induces Ultrastructural Changes of Cardiomyocytes in Mice

  2013cited by this paper
• A Physiologically Based Pharmacokinetic Model to Predict Disposition of CYP2D6 and CYP1A2 Metabolized Drugs in Pregnant Women

  2013cited by this paper
• Food labeling: gluten-free labeling of foods. Final rule.

  2013cited by this paper
• The FDA perspective on VCDs and the importance of continued surveillance

  2013cited by this paper
• A virtual trial framework for quantifying the detectability of masses in breast tomosynthesis projection data.

  2013cited by this paper
• Impact of artificial plaque composition on drug transport.

  2013cited by this paper
• A database for estimating organ dose for coronary angiography and brain perfusion CT scans for arbitrary spectra and angular tube current modulation.

  2012cited by this paper
• Epidemiology and clinical presentations of celiac disease

  2012cited by this paper
• Gluten and celiac disease--an immunological perspective.

  2012cited by this paper
• A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction

  2012cited by this paper
• Sex Differences in the Expression of Drug-Metabolizing and Transporter Genes in Human Liver

  2012cited by this paper
• Dialogues on Diversifying Clinical Trials: Successful Strategies for Engaging Women and Minorities in Clinical Trials

  2012cited by this paper
• Regulatory Innovation in Postmarketing Risk Assessment and Management

  2012cited by this paper
• A Database for Estimating Organ Dose for Chest and Head CT Scans for Arbitrary Spectra and Angular Tube Current Modulation

  2012cited by this paper
• 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2012cited by this paper
• Drug, patient, and physician characteristics associated with off-label prescribing in primary care.

  2012cited by this paper
• TCT-358 Food And Drug Administration Approved Cardiovascular Medical Devices: A Ten Year Review Of The Participation Of Women And Ethnic Subgroups

  2012cited by this paper
• Dietary Supplement Health and Education Act

  2012cited by this paper
• 2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2012cited by this paper
• Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study

  2011influential reference
• Fetal risk from ACE inhibitors in the first trimester

  2011cited by this paper
• Meta-analysis of microarray data using a pathway-based approach identifies a 37-gene expression signature for systemic lupus erythematosus in human peripheral blood mononuclear cells

  2011cited by this paper
• Development and characterization of a dynamic lesion phantom for the quantitative evaluation of dynamic contrast-enhanced MRI.

  2011cited by this paper
• A 5-year review of approved cardiovascular medical devices: are women and ethnic minorities adequately represented?

  2011cited by this paper
• Sex-related differences in QTc effects potential of drugs.

  2011cited by this paper
• Observer variability in the interpretation of HER2/neu immunohistochemical expression with unaided and computer-aided digital microscopy.

  2011cited by this paper
• Computational analysis for hepatic safety signals of constituents present in botanical extracts widely used by women in the United States for treatment of menopausal symptoms.

  2011cited by this paper
• Factors Related to Listeriosis Prevention in Pregnant Women: A Mixed Methods Exploratory Study

  2010cited by this paper
• A statistical, task-based evaluation method for three-dimensional x-ray breast imaging systems using variable-background phantoms.

  2010cited by this paper
• Use and effect of Ephedra weight loss products – a pilot cohort study

  2010cited by this paper
• Increasing participation of women in early phase clinical trials approved by the FDA.

  2009cited by this paper
• Elucidation of Relationship Between Tumor Size and Survival in Non‐Small‐Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development

  2009cited by this paper
• Participation of Women in Clinical Trials for New Drugs Approved by the Food and Drug Administration in 2000–2002

  2009cited by this paper
• Development and validation of a liquid chromatographic method for the simultaneous determination of estradiol, estriol, estrone, and progesterone in pharmaceutical preparations.

  2009cited by this paper
• On the Use of Change in Tumor Size to Predict Survival in Clinical Oncology Studies: Toward a New Paradigm to Design and Evaluate Phase II Studies

  2009cited by this paper
• Black cohosh: Considerations of safety and benefit

  2009cited by this paper
• HIV-Selectest Enzyme Immunoassay and Rapid Test: Ability To Detect Seroconversion following HIV-1 Infection

  2009cited by this paper
• Update on the use of antihypertensive drugs in pregnancy.

  2008cited by this paper
• United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity

  2008cited by this paper
• Outpatient use of cardiovascular drugs during pregnancy

  2008cited by this paper
• Increasing use of antidepressants in pregnancy.

  2007cited by this paper
• Estimating risk of cancer associated with radiation exposure from 64-slice computed tomography coronary angiography.

  2007cited by this paper
• Incident reporting and patient safety

  2007cited by this paper
• Effect of Bone Density on Vertebral Strength and Stiffness After Percutaneous Vertebroplasty

  2007cited by this paper
• The Food and Drug Administration Office of Women's Health: Impact of Science on Regulatory Policy

  2007influential reference
• Novel Approach for Differential Diagnosis of HIV Infections in the Face of Vaccine-Generated Antibodies: Utility for Detection of Diverse HIV-1 Subtypes

  2006cited by this paper
• Comparative Evaluation of HERG Currents and QT Intervals following Challenge with Suspected Torsadogenic and Nontorsadogenic Drugs

  2006cited by this paper
• Major congenital malformations after first-trimester exposure to ACE inhibitors.

  2006influential reference
• Risk of local adverse events by gender following cardiac catheterization

  2006cited by this paper
• Risk of local adverse events following cardiac catheterization by hemostasis device use - phase II.

  2005cited by this paper
• Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry.

  2004cited by this paper
• Prescriptions for contraindicated category X drugs in pregnancy among women enrolled in TennCare.

  2004cited by this paper
• Risk of local adverse events following cardiac catheterization by hemostasis device use and gender.

  2004cited by this paper
• Prescription drug use in pregnancy.

  2004cited by this paper
• Relative risks of reported serious injury and death associated with hemostasis devices by gender

  2003cited by this paper
• Botanical dietary supplement use in peri- and postmenopausal women

  2003cited by this paper
• Osteoporotic fractures.

  2002cited by this paper
• Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA’s Spontaneous Reports Database

  2002cited by this paper
• The n e w e n g l a n d j o u r n a l of m e d i c i n e

  2001cited by this paper
• Drug Safety : Most Drugs Withdrawn in Recent Years Had Greater Health Risks for Women

  2001cited by this paper
• Drug-induced QT prolongation in women during the menstrual cycle.

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Greater quinidine‐induced QTc interval prolongation in women

  2000cited by this paper
• Hormonal Pathology of the Endometrium

  2000cited by this paper
• Women's health.

  1999cited by this paper
• Statement of Organization, Functions, and Delegations of Authority.

  1999cited by this paper
• Effects of toremifene on neonatal rat uterine growth and differentiation.

  1997cited by this paper
• Identification of tamoxifen-DNA adducts formed by 4-hydroxytamoxifen quinone methide.

  1997cited by this paper
• ICI 182,780 inhibits endogenous estrogen-dependent rat uterine growth and tamoxifen-induced developmental toxicity.

  1996cited by this paper
• FDA Office of Women's Health.

  1995cited by this paper
• Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial.

  1994cited by this paper
• Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs; notice.

  1993cited by this paper

• Clinical Trials, Ethics, and Human Protections Policies

  2020cites this paper
• Letter to the Editor: Discussion of the Article “The Emerging Crisis of Stakeholders in Implant-based Augmentation Mammaplasty in Korea”

  2020cites this paper
• Letter to the Editor: The Emerging Crisis of Stakeholders in Implant-based Augmentation Mammaplasty in Korea.

  2020cites this paper
• Cardiovascular Diseases in Women: Policies and Practices Around the Globe to Achieve Gender Equity in Cardiac Health

  2020cites this paper
• US Food and Drug Administration Office of Women's Health: Promoting Therapeutic Optimization in Women

  2020cites this paper
• Sex-Gender Variable: Methodological Recommendations for Increasing Scientific Value of Clinical Studies

  2019cites this paper
• Key steps forward for maternal immunization: Policy making in action.

  2018cites this paper
• Working Together to Address Women's Health in Research and Drug Development: Summary of the 2017 Women's Health Congress Preconference Symposium

  2018cites this paper
• Overcoming Barriers and Identifying Opportunities for Developing Maternal Immunizations: Recommendations From the National Vaccine Advisory Committee

  2017cites this paper
• Women's Lives : A Psychological Exploration, Fourth Edition

  2017cites this paper